Chinese drug approval expected in 2010.

Beijing Med-Pharm and Shanghai Novartis Trading Limited, a subsidiary of Novartis, inked an exclusive agreement to register, market, and distribute Enablex®, which is used to treat symptoms of urinary incontinence, urgency, and urinary frequency related to an overactive bladder (OAB), in China.

Under the terms of the agreement, Beijing Med-Pharm is responsible for attaining China SFDA approval of Enablex, a process that is expected to last through 2010. Once approved, Beijing Med-Pharm will have the exclusive rights to sell, market, and distribute Enablex in China for 10 years.

Previous articleChina SFDA Selects China Aoxing Pharmaceutical to Manufacturer Cancer Pain Drug
Next articleArgenta Discovery and Dr. Reddy’s Achieved First Milestone in Respiratory Disease Collaboration